ASCO 2024 | What are the advantages of subcutaneous nivolumab in kidney cancer?
Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, comments on the benefits of subcutaneous administration of nivolumab, which was assessed in the Phase III CheckMate 67T trial (NCT04810078). Subcutaneous administration is quicker and more convenient than intravenous administration, requiring less infrastructure and lower costs. Therefore, this route of administration will enable therapies to be more accessible to more patients globally. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Leadership – BMS
Honoraria – BMS; Tecnofarma; Tecnofarma
Consulting or Advisory Role – Asofarma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; Janssen Oncology; Merck; MSD; MSD Oncology; Novartis; Novartis; Pfizer
Speakers’ Bureau – Asofarma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Ipsen; Janssen Oncology; Medicamenta; Merck; MSD Oncology; Pfizer; Tecnofarma
Research Funding – Janssen Oncology (Inst); Pfizer
Expert Testimony – Asofarma
Travel, Accommodations, Expenses – Asofarma; Bristol-Myers Squibb (Mexico); Janssen-Cilag; MSD Oncology; Pfizer
Other Relationship – Sanofi
